Top Page
Control Bionics Ltd.
(Sydney:CBL)
Control Bionics Ltd. (CBL) vs. iShares MSCI Australia ETF (EWA)
Control Bionics Ltd. Business Overview & Revenue Model
Control Bionics Ltd. Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.07M | 6.14M | 5.35M | 5.64M | 4.50M | 4.09M |
| Gross Profit | 326.42K | 4.11M | 3.90M | 3.71M | -2.91M | 2.50M |
| EBITDA | -5.50M | -5.14M | -5.01M | -5.14M | -5.92M | -3.40M |
| Net Income | -6.50M | -6.11M | -5.91M | -5.63M | -6.11M | -3.55M |
Balance Sheet | ||||||
| Total Assets | 9.93M | 8.23M | 9.03M | 8.70M | 13.44M | 18.35M |
| Cash, Cash Equivalents and Short-Term Investments | 3.06M | 672.66K | 980.76K | 935.50K | 5.21M | 12.33M |
| Total Debt | 258.10K | 435.40K | 961.74K | 128.50K | 284.82K | 14.87K |
| Total Liabilities | 2.20M | 2.72M | 2.76M | 1.58M | 1.51M | 1.19M |
| Stockholders Equity | 7.73M | 5.51M | 6.27M | 7.15M | 11.92M | 17.16M |
Cash Flow | ||||||
| Free Cash Flow | -4.46M | -4.57M | -5.38M | -4.98M | -5.75M | -4.04M |
| Operating Cash Flow | -4.13M | -4.27M | -4.91M | -4.53M | -5.60M | -3.99M |
| Investing Cash Flow | -704.37K | -744.78K | -473.09K | -457.54K | -147.74K | -53.40K |
| Financing Cash Flow | 6.93M | 4.63M | 5.43M | 706.43K | -87.33K | 14.92M |
Control Bionics Ltd. Technical Analysis
Control Bionics Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$24.72M | -1.40 | -98.14% | ― | 14.84% | 39.64% | |
48 Neutral | AU$50.23M | -9.32 | -417.72% | ― | -34.06% | 75.47% | |
45 Neutral | AU$29.17M | -4.09 | -58.40% | ― | -7.20% | 28.70% | |
39 Underperform | AU$3.12M | -0.88 | -358.43% | ― | -30.80% | -38.95% | |
37 Underperform | AU$10.48M | -0.50 | 459.94% | ― | -2.82% | 32.47% |
Control Bionics Ltd. Corporate Events
Control Bionics has secured formal inclusion of its NeuroNode device in Germany’s Statutory Health Insurance Medical Aids Directory, confirming that the system meets the country’s regulatory, safety, quality and clinical requirements for reimbursement. The listing in Europe’s largest assistive technology market validates the product’s standards, removes a key barrier for distributors and positions the company to roll out a NeuroNode-only wholesale strategy across German-speaking markets.
With reimbursement eligibility now in place, the company plans to appoint a German distribution partner, submit pricing and contracting applications, and begin pilot installations and clinician training at reference sites. Management expects the move to strengthen its European market entry, support expansion into Austria and Switzerland, improve distributor negotiations across the EU and underpin a shift away from direct-to-consumer AAC sales toward scalable partner-led growth.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics director Stephen Rix has increased his direct and indirect holding in the company, primarily via Windward Capital Pty Limited, through an on-market purchase of 587,632 ordinary shares on 27 February 2026. The acquisition, valued at $34,828, lifts his total stake to 6,321,847 shares, signaling increased personal financial commitment by a key board member, which may be viewed positively by investors as a sign of confidence in the company’s prospects.
The transaction did not involve any disposals or changes to director-related contracts, and was executed outside any closed trading period, reducing governance or compliance concerns. This incremental but clear vote of confidence from inside the boardroom could support market sentiment toward Control Bionics, particularly given the importance of insider share purchases as an indicator of management’s outlook in the medtech sector.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics’ U.S. subsidiary has entered an exclusive joint venture-style agreement with NextLevel Assistive Technology to manufacture, assemble, and distribute new UnoTouch Omni and Active iOS-based speech-generating devices in the United States. NextLevel will design and fund the chassis and components, while Control Bionics will serve as FDA Manufacturer of Record, complete final assembly, and leverage its existing distributor network to bring the devices to market.
The capital-light structure is designed to be accretive to revenue, profit, and cash flow, giving Control Bionics exposure to the fast-growing, high-volume iOS tablet-based SGD segment estimated at US$100–150 million annually. The partnership is intended to complement the company’s higher-complexity NeuroNode platform and broaden its AAC offering, with non-binding discussions contemplating potential annual volumes of 1,000–1,500 devices, although there is no certainty these volumes or definitive distribution agreements will be achieved.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited reported a 26% decline in revenue to $2.82 million for the half-year ended 31 December 2025, alongside a sharp increase in net loss after tax to $3.61 million, compared with the prior corresponding period. No dividends were declared, but net tangible assets per share improved to 0.73 cents from 0.49 cents, indicating some balance sheet strengthening despite the deteriorating earnings performance.
The company gained full control of Neuro Elite Athletics, LLC on 31 December 2025, increasing its interest from 20.71% to 100% and transitioning the entity from an associate to a wholly owned subsidiary. While the acquisition did not materially affect the half-year loss due to its timing, the move consolidates Neuro Elite’s operations within the group and may influence future financial performance and strategic positioning in related neuro and performance markets.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited will host an investor webinar on 26 February 2026, following the release of its interim financial report and Appendix 4D, with CEO Jeremy Steele and CFO Shannon Boothroyd presenting a business update and taking questions from investors. The briefing underscores ongoing execution around its NeuroNode assistive communication platform and the commercial rollout of its miniaturised NeuroStrip EMG device, which together position the company to deepen its presence in assistive technologies while opening new diagnostic and performance markets for stakeholders.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics has signed a two-year US distribution agreement with AAC specialist PRC-Saltillo for its NeuroNode technology, formalising a relationship that has already seen PRC staff trained, devices used in trials and demonstrations, and insurance funding secured for clients. The deal broadens access to NeuroNode’s sEMG-based access method as a complementary option within PRC’s communication portfolio, underpins Control Bionics’ strategy of scaling NeuroNode sales through key regional partners, and is expected to support a gradual but sustainable ramp-up of US revenues following its recent partnership with Tobii Dynavox.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics reported a strategically significant December 2025 quarter highlighted by a $3.8 million capital raise to fund commercial, regulatory and manufacturing initiatives across its core platforms, including NeuroNode and NeuroStrip, in the US and Australian markets. The company advanced its NeuroNode distribution strategy through trials with US organisations and, shortly after the quarter, signed a distribution partnership with Tobii, the global AAC leader, while also becoming one of the first organisations to integrate with Apple’s brain–computer interface protocol, reinforcing its technology leadership and enabling closer alignment with mainstream consumer platforms. Control Bionics completed the acquisition of Neuro Elite Athletics (NeuroBounce), creating a dedicated base for its sports performance program and expansion into elite sport, rehabilitation and broader performance markets, and continued the rollout of NeuroStrip, securing usage agreements with high-profile institutions such as the Australian Institute of Sport, Melbourne Victory, Ohio University, The Mayo Clinic, Mountain Land Physical Therapy and The Burrows Institute, supported by the commencement of scaled manufacturing. Quarterly cash receipts were steady at $1.4 million versus a year earlier, with revenue constrained by industry-wide delays in Australia’s NDIS approvals, but the company indicated underlying demand remains robust and said these strategic moves position it well for execution and growth through 2026.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics has signed an agreement with AAC market leader Tobii Dynavox to run a six‑month pilot in five northwestern U.S. states, under which Tobii Dynavox will evaluate offering Control Bionics’ NeuroNode technology alongside its communication aids, replacing a previous U.S. partner. By integrating NeuroNode’s sEMG-based access with Tobii Dynavox’s eye-gaze systems, the collaboration aims to give users an additional, potentially less fatiguing way to control assistive communication technology and, if successful, could pave the way for a broader U.S. rollout and strengthen Control Bionics’ position in the global AAC ecosystem.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited has issued 8,443,747 fully paid ordinary shares on 31 December 2025 without a prospectus or product disclosure statement, relying on provisions of the Corporations Act that allow such an issue to be made to certain investors. The company confirmed it is up to date with its financial reporting and continuous disclosure obligations and stated that there is no undisclosed price-sensitive information, signalling that the new share issue is being conducted within the standard regulatory framework and without additional market-moving information for existing shareholders.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited has applied to the ASX for quotation of 8,443,747 new fully paid ordinary shares under the code CBL, with an issue date of 31 December 2025. The move formalises the listing of these previously announced securities, expanding the company’s quoted share base and potentially increasing liquidity for existing investors while signalling ongoing capital markets activity as the business continues to execute its previously disclosed transactions.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics Limited has lodged a notice with the ASX for a proposed issue of up to 8,443,747 new fully paid ordinary shares. The securities are to be issued via a placement or other type of issue on 31 December 2025, indicating the company is seeking to raise additional equity capital, which may support its ongoing operations or strategic initiatives and result in dilution for existing shareholders depending on the final pricing and allocation.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
Control Bionics has completed the acquisition of 100% of U.S.-based Neuro Elite Athletics, the company behind the NeuroBounce athletic performance program, via its U.S. subsidiary Control Bionics Ngage Inc., making Neuro Elite Athletics a wholly owned subsidiary. The US$370,028 purchase price was settled entirely in equity through the issuance of 8,443,747 new shares under the company’s existing placement capacity, and management says full ownership will accelerate the integration of NeuroBounce with its NeuroStrip EMG platform, supporting a strategic push into high-growth sports performance, return-to-play and human optimisation markets in the U.S. and Australia while consolidating Neuro Elite’s intellectual property, brand, customers and operations within the group.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.